What challenges did Biogenes face in developing their Covid-19 test kit?

Question

Accepted Answer

Biogenes Technologies Encountered Ecosystem Deficiencies and Funding Hurdles in Covid-19 Test Kit Development

Biogenes Technologies faced significant challenges in developing its digital rapid Covid-19 test kit, APTSENS, primarily due to a lack of a robust ecosystem within Malaysia's domestic diagnostic sector. This deficiency impacted their ability to progress through crucial stages such as clinical trials and obtaining regulatory approval, necessitating support from both government agencies and overseas investors. The company's journey highlights the complexities faced by deep tech start-ups in establishing domestic capabilities for advanced diagnostic products.
Lack of Domestic Diagnostic Ecosystem

The development of APTSENS was hindered by what Biogenes described as a lack of an "ecosystem" in Malaysia's domestic diagnostic sector. This suggests a shortfall in the interconnected network of research institutions, manufacturing facilities, skilled personnel, and established supply chains typically required to support the rapid innovation and scaling of diagnostic technologies. Without this foundational infrastructure, Biogenes had to navigate a more fragmented and less supportive environment.
Need for External Funding and Support

To overcome these developmental hurdles, Biogenes relied on support from Malaysian government agencies, including Platcom Ventures, CRADLE, and NTIS. Furthermore, the company secured overseas investment from global venture capital firm Antler South East Asia, based in Singapore. This reliance on external funding underscores the financial demands of deep tech development and the potential difficulty in attracting sufficient domestic capital for such ventures.
Clinical Trial and Regulatory Approval Challenges

Biogenes expressed the hope that with further support from both government and private sectors, they could complete clinical trials and secure regulatory approval to launch APTSENS. This indicates that the path to market for new diagnostic kits in Malaysia involves rigorous testing and a formal approval process, which can be resource-intensive and time-consuming, especially without a well-established regulatory pathway for novel digital diagnostic solutions.

Reading history

Hide →

This history is cleared when the page is closed.

What challenges did Biogenes face in developing their Covid-19 test kit?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

2

0

0

Share with friends